Breathlessness Flashcards
1
Q
Loop Diuretics
Common indications
A
- For relief of breathlessness in acute pulmonary oedema in conjunction with oxygen and nitrates
- For symptomatic treatment of fluid overload in chronic heart failure
- For symptomatic treatment of fluid overload in other oedematous states, e.g. due to renal disease or liver failure, where they may be given in combination with other diuretics
2
Q
Loop Diuretics
MOA
A
- As their name suggests, Loop Diuretics act principally on the ascending limb of the loop of Henle, where they inhibit the Na+/K+/2Cl- co-transporter
- This protein is responsible for transporting sodium, potassium and chloride ions from the tubular lumen into the epithelial cell
- Water then follows by osmosis. Inhibiting this process has a potent diuretic effect
- In addition, loop diuretics have a direct effect on blood vessels, causing dilation of capacitance veins
- In acute heart failure, this reduces pre-load and improves contractile function of the ‘overstretched’ heart muscle
- Indeed, this is probably the main benefit of loop diuretics in acute heart failure, as illustrated by the fact that the clinical response is usually evident before a diuresis is established
3
Q
Loop Diuretics
Adverse effects
A
- Water losses due to diuresis can lead to dehydration and hypotension
- Inhibiting the co-transporter increases urinary losses of sodium, potassium and chloride ions
- Indirectly, this also increases excretion of Mg, Ca and H ions
- You can, therefore, associate loop diuretics with almost any low electrolyte state (including metabolic alkalosis)
- A similar co-transporter is responsible for regulating endolymph composition in the inner ear
- At high doses, loop diuretics can affect this too, leading to hearing loss and tinnitus
4
Q
Loop Diuretics
Warnings
A
- Loop diuretics are contraindicated in patients with severe hypovolemia or dehydration
- They should be used with caution in patients at risk of hepatic encephalopathy (where hypokalaemia can cause or worsen coma)
- Those with severe hypokalaemia and/or hyponatraemia
- Taken chronically, loop diuretics inhibit uric acid excretion and this can worsen gout
5
Q
Loop Diuretics
Interactions
A
- Loop diuretics have the potential to affect drugs that are excreted by the kidneys
- For example, Li levels are increased due to reduce excretion
- The risk of digoxin toxicity may also be increased, due to the effects of diuretic-associated hypokalaemia
- Loop diuretics can increase the ototoxicity and nephrotoxicity of aminoglycosides
6
Q
Loop Diuretics
Communication
A
- Explain to your patient that their body is overloaded with water
- You are therefore offering a treatment to increase urine flow, which will hopefully improve this
- The medicine will inevitably cause them to need to pass water more often
- Provided they do not take doses late in the day it should not affect them at night
7
Q
Loop Diuretics
Monitoring
A
- For efficacy in the acute management of pulmonary oedema, evidence for a good response will include improvements in the patient’s symptoms, tachycardia, HTN, and O2 requirement
- Increased urine output typically occurs later and indicated the onset of the diuretic effect
- In longer-term therapy, you should monitor your patient’s symptoms, signs and body weight (aiming for losses of no more than 1kg/day
- For safety, periodic monitoring of serum sodium, potassium and renal function is also advisable, particularly in the first few weeks of therapy
8
Q
Strong opioid
Common indications
A
- For rapid relief of acute severe pain, including post-operative pain and pain associated with acute myocardial infarction
- For relief of chronic pain, when paracetamol, NSAID, weak opioids are insufficient
- For relief of breathlessness in the context of end-of-life care
- To relieve of breathlessness and anxiety in acute pulmonary oedema, alongside oxygen, furosemide and nitrates
9
Q
Strong opioid
MOA
A
- The term opioids encompass naturally-occurring opiates (e.g. morphine) plus synthetic analogues (e.g. oxycodone)
- Morphine and oxycodone are strong opioids, the therapeutic action of opioids arises from activation of opioid u receptors in the central nervous system
- Activation of the GPCR has several effects that, overall, reduce neuronal excitability and pain transmission
- In the medulla, they blunt the response to hypoxia and hypercapnia, reducing respiratory drive and breathlessness
- By relieving pain, breathlessness and associated anxiety, opioids reduce sympathetic nervous system (fight or flight) activity
- Thus, in myocardial infarction and acute pulmonary oedema, they may reduce cardiac work and oxygen demand, as well as relieving symptoms
- That said, although commonly used, the efficacy and safety of morphine in acute pulmonary oedema is not firmly established
10
Q
Strong opioid
Adverse effects
A
- Opioids cause respiratory depression by reducing respiratory drive
- They may cause euphoria and detachment, and in higher doses, neurological depression
- They can activate the CTZ, causing N&V, although this tends to settle with continued use
- Pupillary constriction occurs due to stimulation of the Edinger-Westphal nucleus
- In the large intestine, activation of u receptors increases smooth muscle tone and reduces motility leading to constipation
- In the skin opioids may cause histamine release, leading to itching, urticaria, vasodilation and sweating
- Continued use can lead to tolerance (a state in which the dose required to produce the same effect increases over time) and dependence
- Dependence becomes apparent on cessation of the opioid, when a withdrawal reaction occurs
11
Q
Strong opioid
Warnings
A
- Most opioids rely on the liver and the kidneys for elimination, so doses should be reduced in hepatic failure and renal impairment in the elderly
- Don’t give opioids in respiratory failure except under senior guidance
- Avoid opioids in billiary colic, as they may cause spasm of the sphincter of Oddi, which may worsen pain
12
Q
Strong opioid
Interactions
A
- Opioids should ideally not be used with other sedating drugs (e.g. antipsychotics, BZs, TCA)
- Where their combination is unavoidable, close monitoring is necessary
13
Q
Strong opioid
Communication
A
- Patients may be reluctant to accept morphine, due to the stigma associated with abuse and dependence
- Explain that it is a highly effective painkiller and that ‘addiction’ is not an issue when it is used for pain control
- That said, you should warn patients that the dose may need to be increased over time as they become tolerant to its effects; this is normal and should not cause alarm.
- Explain how the patient should take their morphine, e.g. CR v IR
- Explain N&V usually settle after a few days, but offer an antiemetic (e.g. metoclopramide)
- Constipation is a very common; pre-emptive use of laxative (e.g. senna), along with good hydration, is advisable
- Advise patients not to drive or operate heavy machinary if they feel drowsy or confused
14
Q
Strong opioid
Monitoring
A
- Acute pain, review your patients response to analgesia within an hour, as well as for adverse effects such as respiratory depression
- For chronic pain, schedule a review after a couple of weeks to assess the need to step up or down the analgesic ladder and/or specialist referral
15
Q
A